Browsing by Author Thurlimann, Beat

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 23  next >
Issue DateTitleAuthor(s)Citation
2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialCoates, Alan; Altermatt, Hans J; Braye, Stephen; Castiglione-Gertsch, Monica; Del Curto, Barbara; Dell'Orto, Patrizia; Gelber, Richard D. (Prof); Goldhirsch, A; Gusterson, Barry; Henriksen, Katrine L; Lacroix-Triki, Magali; Lykkesfeldt, Anne E; Mastropasqua, Mauro G.; Mery, Eliane; Price, K. N.; Rasmussen, Brigitte B; Regan, Meredith M.; Thurlimann, Beat; Viale, Giuseppe; School of Public Health: Public HealthAdjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial, The Lancet, vol.9, N/A, 2008,pp 23-28
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialCoates, Alan; Campone, N; Castiglione-Gertsch, Monica; Forbes, John; Hawle, H; Mouridsen, Henning; Paridaens, R.J.; Price, K. N.; Rabaglio, Manuela; Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthBone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial, Annals of Oncology, vol.20, 9,pp 1489-1498
2007Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; et, al; Forbes, John F.; Keshaviah, Aparna; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Rabaglio, Manuela; Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthCardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.25,(36),2007,pp 5715-5722
2005A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.Coates, Alan; Castiglione-Gertsch, Monica; et, al; Forbes, John F.; Gelber, Richard D. (Prof); Keshaviah, Aparna; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Rabaglio, Manuela; Thurlimann, Beat; School of Public Health: Public HealthA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer., New England Journal of Medicine, vol.353,(26),2005,pp 2747-2757
2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialCoates, Alan; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; Ditzel, Henrik; et al, various; Kammler, Roswitha; Leyland-Jones, Brian; Lyng, Maria; Pagani, Olivia; Regan, Meredith M.; Tang, Weining; Thurlimann, Beat; School of Public Health: Public HealthCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial, Journal of the National Cancer Institute, vol.104, 6, 2012,pp 441-451
2008Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical TrialsCoates, Alan; Castiglione-Gertsch, Monica; Gelber, Richard D. (Prof); Goldhirsch, Aron; Gusterson, Barry A.; Holmberg, Stig B.; Lindtner, Jurii; Mallon, Elizabeth; Murray, E.; Pestalozzi, B. C.; Price, Karen N.; Snyder, Raymond; Thurlimann, Beat; Viale, Giuseppe; Zahrieh, David; School of Public Health: Public HealthDistinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials, Journal of Clinical Oncology, vol.26, 18, 2008,pp 3006-3014
2015ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerCoates, Alan; Abramovitz, Mark; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; et al, Various; Gray, Kathryn P; Kammler, Roswitha; Leyland-Jones, Brian; Long, Bradley; Thurlimann, Beat; Young, Brandon; School of Public Health: Public HealthESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer, Breast Cancer Research and Treatment, vol.154, 3, 2015,pp 543-555
2008Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancerCoates, Alan; Castiglione-Gertsch, Monica; Cole, B F; Collins, John; Crivellari, Diana; Fey, Martin F.; Gelber, Richard D. (Prof); Goldhirsch, A; Golouh, Rastko; Gruber, G; Gusterson, Barry; Holmberg, Stig B.; Lindtner, Jurii; Price, K. N.; Simoncini, Edda; Thurlimann, Beat; School of Public Health: Public HealthExtracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer, Annals of Oncology, vol.19, N/A, 2008,pp 1393-1401
2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; et, al; Forbes, John F.; Gelber, Richard D. (Prof); Keshaviah, Aparna; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Thurlimann, Beat; School of Public Health: Public HealthFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.25,(5),2007,pp 486-492
2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Collins, John; Crivellari, Diana; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Holmberg, Stig B.; Price, Karen; Thurlimann, Beat; School of Public Health: Public HealthIs chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93., Breast Cancer Research and Treatment, vol.113,(N/A),2009,pp 137-144
2008Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; Chirgwin, Jacquie H; Colleoni, Marco; Crivellari, Diana; Del Mastro, Lucia; Forbes, John F.; Gelber, Richard D. (Prof); Gladieff, Laurence; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Rabaglio, Manuela; Smith, Ian (Prof); Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthLetrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, 12, 2008,pp 1972-1979
2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.Coates, Alan; et al, various; Forbes, John F.; Giobbie-Hurder, Anita; Goldhirsch, Aron; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Smith, Ian (Prof); Thurlimann, Beat; School of Public Health: Public HealthLetrozole therapy alone or in sequence with tamoxifen in women with breast cancer., New England Journal of Medicine, vol.361, 8,pp 766-776
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2012Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 TrialCoates, Alan; Bonnefoi, Herve; Ejlertsen, Bent; et al, Various; Ewertz, Marianne; Forbes, John F.; Gray, Kathryn P; Paridaens, R.J.; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Thurlimann, Beat; School of Public Health: Public HealthObesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial, Journal of Clinical Oncology, vol.30, 32, 2012,pp 3967-3975
2009Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.Coates, Alan; Castiglione-Gertsch, Monica; Collins, John; et al, various; Fey, Martin F.; Gelber, RD; Holmberg, Stig B.; Lindtner, Jurij; Pagani, O.; Price, K. N.; Thurlimann, Beat; School of Public Health: Public HealthPatterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century., Breast Cancer Research and Treatment, vol.117, 2,pp 319-324
2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialCoates, Alan; Debled, M.; et, al; Forbes, John F.; Keshaviah, Aparna; Lang, I.; Mauriac, L; Monnier, Arnaud; Mouridsen, Henning; Paridaens, Robert; Thurlimann, Beat; School of Public Health: Public HealthPredictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Annals of Oncology 2005, vol.18,(5),2007,pp 859-867
2008Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?Coates, Alan; et al, Various; Fleming, G. F.; Francis, P A; Pagani, Olivia; Perez, E. A.; Price, K N; Regan, Meredith M.; Thurlimann, Beat; Torrisi, R; Walley, B; School of Public Health: Public HealthPremenopausal endocrine-responsive early breast cancer: who receives chemotherapy?, Annals of Oncology, vol.19, 7, 2008,pp 1231-1241
2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trialsCoates, Alan; Gelber, Richard D. (Prof); Gelber, S.; Goldhirsch, Aron; Huober, J; Ohlschlegel, Christian; Price, K. N; Regan, Meredith M.; Thurlimann, Beat; Viale, Giuseppe; School of Public Health: Public HealthPrognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials, Annals of Oncology, vol.23, 11, 2012,pp 2843-2851